The European Patent Office Issued a Preliminary Non-binding Opinion that the Turzi and Regenlab European PRP Patent is Invalid

Wednesday, April 11, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

HOLON, Israel, April 11, 2018 /PRNewswire/ --

In its official opinion, the opposition division

of the European Patent Office found the Turzi blood separation patent, which is licensed to Regenlab, to be invalid on the grounds of added matter, lack of novelty and lack of sufficient disclosure

Estar

Technologies Ltd. (Estar), a leading global developer and manufacturer of innovative medical technologies in the biologics, regenerative medicine and platelet rich plasma (PRP) fields, announced today that the European patent Office (EPO) has issued on March 29, 2018 a preliminary non-binding opinion on the validity of Patent No. 2,073,862 B1 in the name of Antoine Turzi (Turzi), licensed to Regen Lab SA.

In this preliminary opinion, the opposition division of the EPO found the Turzi patent to be invalid on the grounds of (i) added matter, (ii) lack of novelty, and (iii) lack of sufficient disclosure. With respect to the prior disclosure issue, the Opposition Division of the EPO found that "it is shown beyond any reasonable doubt that the product was available prior to priority, a prior use had taken place and the features of the product could be investigated."

The decision will be made after oral proceedings, now scheduled for November, 2018. The opinion is preliminary and non-binding. 

"We are pleased and extremely encouraged by the EPO current view of the Turzi/Regenlab patent," stated Aaron Esteron, the CEO of Estar. 

Unless the Opposition Division of the EPO changes its views very significantly at an oral hearing, the result will be the complete invalidation and revocation of Turzi and Regenlab main patent in all contracting states of the European Patent Convention.

About Estar Technologies Ltd.  Founded in 1991, Estar is a global leader and innovator in the biologics and platelet rich plasma arena. Estar's products are globally marketed mainly under the renowned TropocellsŪ and CellenisŪ brands. Estar has developed a unique and effective technology for the simple preparation of pure PRP by enabling the physician to easily and effectively separate and concentrate growth factors taken from the patient's own blood for the purpose of building new tissues and effectively accelerate the natural autologous wound healing process.

Additional information about Estar can be found at http://www.estar-medical.com.

Contact: Yuval Esteron yuval@estar-medical.com

SOURCE Estar Technologies Ltd. (Estar)



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store